08:18 AM EDT, 05/22/2025 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) on Thursday said it is finalizing site initiation for the first locations to be used in its Phase 2 Utopia (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.

The company, which is developing cannabinoid-based drug candidates for pain management, said the Phase 2 trial will consist of two parts. Utopia-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained will guide the strategy for Utopia-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population.

Patient enrollment for Utopia-1 is expected to begin early next month across multiple sites in Canada, with interim data anticipated in mid-summer this year.